Question · asked by 1 review

Antipsychotic dose increase vs antipsychotic dose continuation: Adverse effects – leaving the study early due to adverse effects – overall tolerability – total

It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Antipsychotic dose increase vs antipsychotic dose continuation
Leaving the study early: tolerability ‐ leaving early due to adverse effects. · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).
Increasing antipsychotic dose for non response in schizophrenia (2018) · Cochrane Headline outcomes only
RR 1.63 [0.52, 5.07]7 studies · 496 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Increasing antipsychotic dose for non response in schizophrenia
2018 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.